Undisclosed CD19/BCMA CAR-iNK / Tome Biosci - LARVOL DELTA

Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT (GlobeNewswire) - "Tome Biosciences, Inc...today presented preclinical data highlighting its progress in developing PGI as integrative gene and cell therapies at ASGCT’s 27th Annual Meeting in Baltimore, MD...Unveiled the Company’s lead programs in integrative gene therapy as PKU and cell therapy as a CD19/BCMA CAR-iNK for renal autoimmune diseases...The data presented included both in vivo evidence of CD19 killing in mice and in vitro B cell killing in blood samples from patients with lupus...Reported on previously undescribed challenges with reverse transcriptase-mediated writing of long (~40bp) sequences in rodent non-dividing cells and potential solutions."

New molecule • Preclinical • Immunology • Lupus